Biomea Fusion, Inc. (BMEA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
900 Middlefield Road
Redwood City, CA 94063
United States of America (the)
Phone
650 980 9099
Website
Sector
Healthcare
Industry
Biotechnology
Employees
79
First IPO Date
April 16, 2021
| Name | Title | Pay | Year Born |
| Michael J. Hitchcock | Interim Chief Executive Officer & Director | 867,935 | 1950 |
| Ramses Erdtmann | Co-Founder, President, Chief Operating Officer & Director | 636,485 | 1963 |
| Caroline Perez- Dupont | Senior Vice President of Legal | 0 | N/A |
| Heow Tan | Chief Technology & Quality Officer | 0 | 1959 |
| Stephan Morris | Chief Development Officer | 0 | N/A |
| Ravi Upasani | Executive Vice President of Intellectual Property | 0 | N/A |
| Thorsten Kirschberg | Executive Vice President of Research | 0 | 1970 |
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.